Question to the Department of Health and Social Care:

To ask His Majesty's Government what discussions they have had, or are intending to have, with (1) Takeda Pharmaceuticals, and (2) EGFR Positive UK, following the withdrawal of the drug Mobocertinib from the UK market.

The Medicines and Healthcare products Regulatory Agency (MHRA) is engaging with Takeda Pharmaceuticals. This is to ensure that where appropriate, patients can have continued access to Mobocertinib following its withdrawal from the United Kingdom market.

The MHRA has not had discussions with EGFR Positive UK, but if approached would answer any questions they may have regarding the withdrawal of Mobocertinib from the UK market.